(Q39815528)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19662633%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

title

In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19662633%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19662633%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Asis Palazon

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19662633%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Carlos Alfaro

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19662633%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Maria C. Ochoa

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19662633%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

José Luis Pérez-Gracia

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19662633%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Sandra Hervas-Stubbs

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19662633%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Ignacio Melero, MD-PhD

14

object named as

Ignacio Melero

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19662633%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

author name string

Oihana Murillo

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19662633%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Juan Dubrot

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19662633%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Ainhoa Arina

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19662633%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Arantza Azpilikueta

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19662633%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Sarai Solano

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19662633%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Izaskun Gabari

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19662633%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Pedro Berraondo

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19662633%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

language of work or name

English

0 references

publication date

1 September 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19662633%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Immunology

4 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19662633%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

volume

39

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19662633%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19662633%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

page(s)

2424-2436

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19662633%20AND%20SRC:MED&resulttype=core&format=json

Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?

4 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

TNF/TNFR family members in costimulation of T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

CD137 stimulation delivers an antigen-independent growth signal for T lymphocytes with memory phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

IL-15-dependent induction of 4-1BB promotes antigen-independent CD8 memory T cell survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

Combined CD137 (4-1BB) and adjuvant therapy generates a developing pool of peptide-specific CD8 memory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

Identification of regulatory functions for 4-1BB and 4-1BBL in myelopoiesis and the development of dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

Cutting edge: Expression of functional CD137 receptor by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

Genes that distinguish physiological and pathological angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

Immune surveillance against a solid tumor fails because of immunological ignorance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

Cross-presentation, dendritic cells, tolerance and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

On cross-priming of MHC class I-specific CTL: rule or exception?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

Mini‐review: Regulation of cytotoxic T lymphocyte responses by dendritic cells: peaceful coexistence of cross‐priming and direct priming?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

Constitutive versus activation-dependent cross-presentation of immune complexes by CD8(+) and CD8(-) dendritic cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

The CD8+ dendritic cell subset selectively endocytoses dying cells in culture and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

Intratumoural administration of dendritic cells: hostile environment and help by gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

Identification of a dendritic cell receptor that couples sensing of necrosis to immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

T cell receptor antagonist peptides induce positive selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

Chance encounters and organized rendezvous.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

Selective suicide of cross-presenting CD8+ dendritic cells by cytochrome c injection shows functional heterogeneity within this subset

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

CD11chigh dendritic cell ablation impairs lymphopenia-driven proliferation of naive and memory CD8+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

4-1BB functions as a survival factor in dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

4-1BB-mediated immunotherapy of rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

Signal 3 availability limits the CD8 T cell response to a solid tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

Immunosuppressive networks in the tumour environment and their therapeutic relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

Antigen crosspresentation by human plasmacytoid dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

DC ablation in mice: promises, pitfalls, and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

A novel CD11c.DTR transgenic mouse for depletion of dendritic cells reveals their requirement for homeostatic proliferation of natural killer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

Eradication of established tumors in mice by a combination antibody-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

Combined natural killer T-cell based immunotherapy eradicates established tumors in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

Improving efficacy of interleukin-12-transfected dendritic cells injected into murine colon cancer with anti-CD137 monoclonal antibodies and alloantigens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

Cutting Edge: Intravenous Soluble Antigen Is Presented to CD4 T Cells by CD8- Dendritic Cells, but Cross-Presented to CD8 T Cells by CD8+ Dendritic Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

Activation of Dendritic Cells That Cross-Present Tumor-Derived Antigen Licenses CD8+ CTL to Cause Tumor Eradication

21 January 2018

2 references

https://api.crossref.org/works/10.1002%2FEJI.200838958

21 January 2018

https://api.crossref.org/works/10.1002%2FEJI.200838958

7 January 2021

Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

7 January 2021

Ligation of CD137 receptor prevents and reverses established anergy of CD8+ cytolytic T lymphocytes in vivo

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

7 January 2021

Redundancy of direct priming and cross-priming in tumor-specific CD8+ T cell responses

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

7 January 2021

Mechanisms involved in synergistic anticancer immunity of anti-4-1BB and anti-CD4 therapy

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

7 January 2021

Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

7 January 2021

Tumor progression despite efficient tumor antigen cross-presentation and effective "arming" of tumor antigen-specific CTL

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

7 January 2021

Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

7 January 2021

Immunogenic cell death and cross-priming are reaching the clinical immunotherapy arena

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

7 January 2021

Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838958

7 January 2021